头孢哌酮舒巴坦+盐酸氨溴索治疗慢阻肺患者的效果评价

Evaluation of the Efficacy of Cefoperazone Sulbactam + ambroxol Hydrochloride in Patients with Chronic Obstructive Pulmonary Disease

目的 研究头孢哌酮舒巴坦+盐酸氨溴索治疗慢阻肺患者的效果。方法 方便选择该院在2016年8月-2019年2月期间收治的慢阻肺患者60例,将其随机分为对照组(30例)与观察组(30例),对照组患者给予头孢他啶联合盐酸氨溴索进行治疗,观察组患者给予头孢哌酮舒巴坦联合盐酸氨溴索进行治疗,对比分析两组患者的治疗效果、治疗前后动脉血二氧化碳分压(PaCO2)、动脉血氧分压(PaO2)、主要症状消失时间、住院时间以及不良反应发生情况等。结果 观察组患者的治疗总有效率96.67%显著高于对照组76.67%,差异有统计学意义(χ^2=17.311,P<0.05);治疗前两组患者的PaCO2、PaO2对比,差异无统计学意义(t=0.328,0.481,P>0.05),但治疗后两组患者的PaCO2、PaO2较治疗前均有明显变化,观察组患者的PaCO2(40.90±7.32)mmHg显著低于对照组(47.37±8.11)mmHg,其PaO2(70.68±15.49)mmHg显著高于对照组(61.35±11.56)mmHg,差异有统计学意义(t=3.244,2.644,P<0.05);观察组患者的喘息、咳嗽症状消失时间以及住院时间均明显短于对照组,差异有统计学意义(t=9.621,4.051,3.621,P<0.05);观察组患者的不良反应发生率6.67%明显低于对照组23.34%,差异有统计学意义(χ^2=10.895,P<0.05)。结论 针对慢阻肺患者采用头孢哌酮舒巴坦联合盐酸氨溴索进行治疗效果更佳,能够有效提高患者的治疗效果,缓解临床症状,缩短住院时间,促进患者身体康复,有利于改善患者的生活质量,具有临床应用价值。

Objective To study the effect of cefoperazone sulbactam+ambroxol hydrochloride in the treatment of patients with chronic obstructive pulmonary disease.Methods Convenient selected sixty patients with chronic obstructive pulmonary disease admitted to the hospital from August 2016 to February 2019 were randomly divided into the control group(30 cases)and the observation group(30 cases).The control group received ceftazidime combined with hydrochloric acid.Ambroxol was used for treatment.Patients in the observation group were treated with cefoperazone sulbactam and ambroxol hydrochloride.The therapeutic effects of the two groups were compared.The arterial blood carbon dioxide partial pressure(PaCO2)and arterial oxygen partial pressure(PaO2)before and after treatment were compared,as well as the time of disappearance of main symptoms,length of hospital stay,and occurrence of adverse reactions.Results The total effective rate of treatment in the observation group was 96.67%significantly higher than that in the control group 76.67%,The difference was statistically significant(χ^2=17.311,P<0.05).There was no significant difference in PaCO2 and PaO2 between the two groups before treatment(t=0.328,0.481,P>0.05),but the PaCO2 and PaO2 of the two groups were significantly different after treatment.The PacO2(40.90±7.32)mmHg of the observation group was significantly lower than that of the control group(47.37±8.11)mmHg,and the PaCO2(70.68±15.49)mmHg was significant,higher than the control group(61.35±11.56)mmHg,The difference was statistically significant(t=9.621,4.051,3.621,P<0.05);The incidence of adverse reactions in the observation group was 6.67%,which was significantly lower than that in the control group 23.34%,The difference was statistically significant(χ^2=10.895,P<0.05).Conclusion Cefoperazone sulbactam combined with ambroxol hydrochloride is better for patients with COPD,which can effectively improve the patient's therapeutic effect,relieve clinical symptoms,shorten hospital stay,promote physical rehabilitation,and improve patients'quality of life has clinical application value.